TrialJournal for immunotherapy of cancer2022

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.

Claire F Friedman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.